Christopher Schaber - Soligenix Chairman, CEO and Pres
| SNGX Stock | USD 3.35 0.02 0.60% |
Chairman
Dr. Christopher J. Schaber, Ph.D., is Chairman of the Board, President, Chief Executive Officer of Soligenix Inc., he has over 28 years of experience in the pharmaceutical and biotechnology industry. He was our President and Chief Executive Officer and a director since August 2006. He was appointed Chairman of the Board on October 8, 2009. He also has served on the board of directors of the Biotechnology Council of New Jersey since January 2009 and the Alliance for Biosecurity since October 2014, and was a member of the corporate councils of both the National Organization for Rare Diseases and the American Society for Blood and Marrow Transplantation since October 2009 and July 2009, respectively. Prior to joining Soligenix, He served from 1998 to 2006 as Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc., where he was responsible for overall pipeline development and key areas of commercial operations, including regulatory affairs, quality control and assurance, manufacturing and distribution, preclinical and clinical research, and medical affairs, as well as coordination of commercial launch preparation activities. From 1996 to 1998, Dr. Schaber received his BA degree from Western Maryland College, his MS degree in Pharmaceutics from Temple University School of Pharmacy and his PhD degree in Pharmaceutical Sciences from the Union Graduate School. Dr. Schaber was selected to serve as a member of our Board of Directors because of his extensive experience in drug development and pharmaceutical operations, including his experience as an executive senior officer with our Company and Discovery Laboratories, Inc., and as a member of the board of directors of BioNJ because of his proven ability to raise funds and provide access to capital and because of his advanced degrees in science and business. since 2009.
| Age | 58 |
| Tenure | 15 years |
| Address | 29 Emmons Drive, Princeton, NJ, United States, 08540 |
| Phone | (609) 538-8200 |
| Web | https://www.soligenix.com |
Christopher Schaber Latest Insider Activity
Tracking and analyzing the buying and selling activities of Christopher Schaber against Soligenix stock is an integral part of due diligence when investing in Soligenix. Christopher Schaber insider activity provides valuable insight into whether Soligenix is net buyers or sellers over its current business cycle. Note, Soligenix insiders must abide by specific rules, including filing SEC forms every time they buy or sell Soligenix'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Christopher Schaber over three months ago Acquisition by Christopher Schaber of 3530 shares of Soligenix at 1.4198 subject to Rule 16b-3 | ||
Christopher Schaber over six months ago Acquisition by Christopher Schaber of 10770 shares of Soligenix at 0.93 subject to Rule 16b-3 | ||
Christopher Schaber over six months ago Purchase by Christopher Schaber of 7000 shares of Soligenix | ||
Christopher Schaber over six months ago Acquisition by Christopher Schaber of 150000 shares of Soligenix subject to Rule 16b-3 |
Soligenix Management Efficiency
The company has return on total asset (ROA) of (0.4514) % which means that it has lost $0.4514 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.398) %, meaning that it created substantial loss on money invested by shareholders. Soligenix's management efficiency ratios could be used to measure how well Soligenix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.66 in 2024. Return On Capital Employed is likely to rise to -2.01 in 2024. At this time, Soligenix's Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 92.2 K in 2024, whereas Non Current Assets Total are likely to drop slightly above 275.5 K in 2024.Similar Executives
| Found 2 records | CHAIRMAN Age | ||
| Robert Bitterman | Phio Pharmaceuticals Corp | 73 | |
| William Schmidt | Ensysce Biosciences | 73 | |
Management Performance
| Return On Equity | -1.4 | ||||
| Return On Asset | -0.45 |
Soligenix Leadership Team
Elected by the shareholders, the Soligenix's board of directors comprises two types of representatives: Soligenix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Soligenix. The board's role is to monitor Soligenix's management team and ensure that shareholders' interests are well served. Soligenix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Soligenix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Oreola Donini, Chief Scientific Officer and Sr. VP | ||
| Christopher Schaber, Chairman, CEO and Pres | ||
| Richard Dunning, Ex Officer | ||
| CGMA CPA, CFO VP | ||
| MSc MD, Senior Officer |
Soligenix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Soligenix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.4 | ||||
| Return On Asset | -0.45 | ||||
| Operating Margin | (21.60) % | ||||
| Current Valuation | 706.87 K | ||||
| Shares Outstanding | 2.51 M | ||||
| Shares Owned By Insiders | 0.02 % | ||||
| Shares Owned By Institutions | 2.63 % | ||||
| Number Of Shares Shorted | 45.98 K | ||||
| Price To Earning | (1.67) X | ||||
| Price To Book | 1.41 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Soligenix Stock Analysis
When running Soligenix's price analysis, check to measure Soligenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Soligenix is operating at the current time. Most of Soligenix's value examination focuses on studying past and present price action to predict the probability of Soligenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Soligenix's price. Additionally, you may evaluate how the addition of Soligenix to your portfolios can decrease your overall portfolio volatility.